Background: Primary endocrine therapy is used as an alternative to surgery in up to 40 per cent of women with early breast cancer aged over 70 years in the UK. This study investigated the impact of surgery versus primary endocrine therapy on breast cancer-specific survival (BCSS) in older women. 
Introduction
In the UK, women over the age of 70 years account for more than 30 per cent of all diagnoses of breast cancer 1 . Treatment of older patients with breast cancer in the UK differs from that recommended by national guidelines across the spectrum of therapy 2, 3 . Rates of breast surgery for operable disease are lower in women aged over 70 years than for younger patients 3, 4 . In addition, practice varies by UK health region, with rates of surgery ranging from 60 to 88 per cent. These differences in surgery rate cannot be accounted for by case mix 5 . Older women in other developed nations, such as the Netherlands and the Republic of Ireland, are less likely to receive surgery for breast cancer than their younger counterparts, but the discrepancy is smaller than that observed in the UK 6, 7 . In the USA, rates of surgical treatment for stage I-II disease remain over 90 per cent for patients aged 90 years or more 8 .
Relative survival for breast cancer in the UK is inferior to that seen in a number of other developed nations, particularly in the older age groups 9 . This pattern persists after accounting for stage at diagnosis, suggesting that some of the discrepancy is due to suboptimal management rather than late presentation.
For women with oestrogen receptor (ER)-positive operable breast cancer, primary endocrine therapy is the main alternative to surgery. Primary endocrine therapy in this context is defined as treatment with an antioestrogen, such as tamoxifen or an aromatase inhibitor, without surgical intent. Historical randomized trials of primary endocrine therapy compared with surgery, both with and without adjuvant tamoxifen, suggested that, among women aged 75 years or over, there was no evidence of a difference in either overall survival or breast cancer-specific survival (BCSS) between the two approaches at a median follow-up of 5 years 10 . On very long-term follow-up, survival outcomes in the non-surgical group were inferior 11 , as to be expected considering that secondary antioestrogen resistance develops with time. There is evidence to suggest that women in the 70-75-year age range may benefit from surgery even at 5-year follow-up 12 . Local disease control was considerably worse with primary endocrine therapy, even at short-and medium-term follow-up 11 -13 , with a significantly greater number of patients requiring a change of management on disease progression. However, the trials were flawed by modern standards; patients with co-morbidities were excluded and the surgical therapies were often substandard, with no adjuvant chemotherapy, and no chest wall or breast radiotherapy. As a result, the trial populations did not reflect the heterogeneity in health states typical of the older population, or the sophistication of modern breast cancer care. Furthermore, these trials did not reflect the advances in surgical and anaesthetic techniques, the introduction of third-generation aromatase inhibitors or the increase in life expectancy over the past four decades (from 75⋅3 years in 1971 to 83⋅2 years in 2012-2014) 14 . Rates of mortality and morbidity after modern-day breast cancer surgery were very low in a recent national UK audit 15 , suggesting that surgery is safe in the majority of older woman. The historical trials may no longer fully represent modern practice and outcomes.
A recent review 10 of evidence from non-randomized cohort studies suggested that surgery may be more effective than primary endocrine therapy in terms of BCSS. Cohort studies are often better able to include representative populations, and provide information on outcomes of treatment in a real-world clinical setting. However, the studies included in this review did not attempt to account for the differing patient characteristics between women treated with surgery and those who had primary endocrine therapy. On average, women are more likely to receive primary endocrine therapy if they are older and have chronic co-morbidities 16, 17 . This confounds overall survival estimates and increases estimates of non-breast cancer mortality in non-surgically treated patients. Similarly, disease characteristics such as stage at diagnosis and tumour grade are associated with treatment choice. Bates and colleagues 17 reported that large tumour size (over 5 cm) and node positivity were associated with non-surgical treatments, suggesting that selection bias by stage of disease may confound the outcomes of observational studies in favour of surgery. In addition, women who have surgery are usually those with early-stage disease as surgery is not appropriate or possible in advanced breast cancer. Outcomes in the non-surgical group may appear worse if women with advanced disease remain understaged and are mistakenly categorized as having early-stage disease. This leads to confounding in estimates of BCSS. Observed differences in outcomes seen in these cohort studies cannot, therefore, be assumed to be explained solely by type of treatment. Another issue with observational data is that cause of death may be misclassified as breast cancer, whereas efforts to establish the actual cause of death may be more rigorous in a randomized trial.
There are significant barriers to conducting sufficiently powered RCTs in older patients with breast cancer 18 . The ESTEeM (Endocrine +/-Surgical Therapy for Elderly women with Mammary cancer) trial was a recent attempt to conduct an age-and fitness-stratified randomized trial to compare these treatment approaches. It failed, with the study closing in 2009, owing to slow recruitment 18 . In light of this, it is necessary to make use of observational evidence, combined with mathematical modelling and adjusting for issues such as confounding, in order to assess how treatment choices influence outcomes.
The aim of this study was to investigate how current UK practice in the surgical treatment of older women (aged over 70 years) with breast cancer affects breast cancer survival at the population level. A retrospective cohort analysis was conducted using UK Cancer Registry data. The data were collected routinely from two English cancer registration regions that are demographically representative of the wider UK population (West Midlands, Northern and Yorkshire). The effect of primary endocrine therapy versus surgical treatment on survival outcomes was assessed using exploratory data analysis and survival analysis methods.
Methods
Data on all first diagnoses of invasive breast cancer in women aged 70 years and over between 2002 and 2010 were acquired from two UK cancer registry regions (West Midlands, Northern and Yorkshire). Variables provided for analysis are shown in Table 1 . The patient and disease variables are representative of wider UK national data in terms of age distribution, deprivation pattern, tumour stage and biological subtype distributions. Survival data were derived from death certifications from the Office for National Statistics. Time to death was defined as the interval in days between the date of diagnosis and the date Values in parentheses are percentages. Oestrogen receptor (ER) status is shown for completeness, but ER-negative tumours were excluded from further analysis. Missing values for grade, size, lymph node status and co-morbidities were addressed before modelling, using multiple imputation. Patients with stage IV disease and those who died within 91 days of diagnosis were excluded after the multiple imputation (as they were likely to have had advanced disease or to be otherwise unable to benefit from breast cancer treatment). HER2, human epidermal growth factor receptor 2; CCI, Charlson Co-Morbidity Index.
of death. Patients who remain alive were censored. Cause of death was recorded by the registry as either breast cancer, other (cancer), other (non-cancer), other (unknown) or unknown. For the purposes of this analysis, deaths were classified dichotomously as either from breast cancer or not from breast cancer. The data in Table 1 had been preprocessed as described in Table S1 (supporting information). In particular, ER status was not recorded completely for all patients, predominantly in the Northern and Yorkshire region. In the West Midlands, 14⋅5 per cent of patients had data missing on ER status over the 2002-2010 interval. In the Northern and Yorkshire region, ER status was not available for patients diagnosed before 2010, and 35 per cent of patients had missing data in 2010. Patients with missing ER status who had received hormone therapy were assumed to have had ER-positive disease. This was justified by the fact that hormone therapy is only effective for, and offered to, patients with ER-positive disease, which was routinely tested for throughout this time interval; it is therefore reasonable to suppose that hormone therapy would not have been given to women with ER-negative tumours. Previous internal data quality audits by the cancer registry have shown that hormone therapy data are reliable for the Northern and Yorkshire region.
Data on surgical procedures were available from linked records of treatment episodes. These include the OPCS-4 code of the procedure(s) received along with the date of the episode. A patient was classed as receiving primary surgery if they had an episode including a procedure indicating breast surgery recorded within 6 months of diagnosis; a sensitivity analysis of this 6-month rule was carried out. Co-morbidity was derived from linked records in the Hospital Episode Statistics data set and aggregated using the Charlson Co-morbidity Index (CCI) 19 by counting diagnostic codes recorded in episodes in the 18 months before diagnosis, an approach used in other studies using routine registration data 20 .
Statistical analysis
Exploratory survival analysis consisted of plotting cumulative incidence curves for breast cancer and other-cause mortality for patients treated surgically and those who received primary endocrine therapy. The effect of treatment and other co-variables on BCSS was estimated using two models. The first was the commonly used Cox proportional hazards model 21 , which estimates the effects of co-variables on survival outcomes but makes no assumptions about the shape of the underlying survival curve. The second was the Royston-Parmar model 22 Table 2 Estimate of non-time-varying hazard ratios for breast cancer mortality from the Royston-Parmar restricted cubic spline model
Values in parentheses are 95 per cent confidence intervals. CCI, Charlson Co-Morbidity Index.
relaxes the proportional hazards assumption, allowing the effect of a co-variable to vary over time. On the basis of exploratory analysis, the effects of age at diagnosis and treatment options (surgery or primary endocrine therapy) were modelled as time-varying and the others were modelled as time-invariant. The Royston-Parmar model (Fig. S1 , supporting information) also specifies a flexible functional form for the underlying hazard, making it easier to extrapolate to predictions of future outcomes.
The registry data contained a number of variables with a non-negligible proportion of missing values ( Table 1) . If every patient with any missing data had been excluded from the analysis, much useful information would have been lost. Furthermore, because certain subgroups of patients are more likely to have missing data, the results would be biased by the exclusions. To mitigate these issues, the method of multiple imputation was used before fitting the models. For each patient for whom one or more variables were missing, the distribution of these variables in patients with similar characteristics was used to impute values for the missing variables. In this way, the data set was completed in a probabilistically plausible manner. To account for the randomness in completing the data set in this way, the multiple imputation was repeated to create a collection of 1000 completed data sets. The modelling was carried out on each of these complete data sets, and the results were combined to produce a final result that makes maximal use of the information in the data but avoids the bias of being based on any individual imputed data set. Further details of the imputation process are included in Table S2 (supporting  information) .
Exploratory analysis and derivation of the final models were carried out using the open-source statistical package R (version 3.0.1) 23 . The user-contributed CRAN R package mi was used to implement the method of multiple imputation with chained equations 24 . The Royston-Parmar model was implemented using Stata ® version 13 (StataCorp, College Station, Texas, USA), via the module stpm2 25 .
Results
The cumulative incidence of breast cancer and other-cause mortality for patients treated surgically (10 087 patients) and non-surgically (8643) was derived, after removing patients with ER-negative disease and early deaths (within 91 days) (Fig. 1) . Five-year BCSS rates in the primary endocrine therapy and surgery groups were 69⋅4 and 89⋅9 per cent respectively. Kaplan-Meier estimates of BCSS by stage and for unknown stage at diagnosis (Fig. 2) , and by age group and number of co-morbidities, are shown in Figs 2 and 3 respectively. The curves by stage demonstrate that BCSS was inferior in patients treated with primary endocrine therapy compared with those who received surgery, regardless of stage at diagnosis. For patients with unknown stage at diagnosis, there was a sharp drop in BCSS in the first few months for patients treated with primary endocrine therapy. This may reflect the fact that some patients in this group had undiagnosed advanced disease at diagnosis. Fig. 3 demonstrate that BCSS remained inferior for patients receiving primary endocrine therapy, despite increasing age. The same was true for increasing numbers of co-morbidities, except for those in the highest co-morbidities category. Here, the degree of separation between outcomes and the width of the confidence intervals make the difference less distinct. It is less clear that the choice of primary endocrine therapy had a detrimental effect in this group.
The curves in
The survival models were fit to the data sets following multiple imputation. The results of the Cox proportional hazards model (Table S3 , supporting information) and Royston-Parmar model ( Table 2 and Fig. 4; Fig. S2 , supporting information) demonstrate the effect of treatment and other co-variables on BCSS. The estimates from f CCI score ≥ 3 Fig. 4 . The hazard ratio was approximately constant at around 0⋅37 from year 3 onwards. Hazard ratios for other co-variables from the Royston-Parmar model show that patients with higher tumour grade, larger tumour size and lymph node involvement had a higher risk of breast cancer mortality ( Table 2) . Screen detection was associated with a considerably lower risk of breast cancer mortality. There were also small increases in breast cancer mortality associated with increased numbers of co-morbidities and with income deprivation. The sensitivity of the results to changing the time horizon for the surgery rule is shown in Table S4 , and Figs S3 and S4 (supporting information).
Discussion
The results of this analysis show that, in a cohort of older women with ER-positive breast cancer in the UK, the risk of breast cancer death was greater in patients treated with primary endocrine therapy than among those who received surgery. Assuming this reflects a true underlying difference in risk between the two treatment approaches, this will translate into a difference in overall survival. The difference was greatest in patients who would otherwise have a high underlying life expectancy, that is younger and healthier patients. For older, frailer patients, the high risk of death from non-breast cancer causes means that the risk of breast cancer death would have less relative impact on overall survival, so the effect of non-surgical treatment on survival outcomes would be smaller. In some patients, the difference may be so small that primary endocrine therapy would be the preferred treatment option in order to avoid any potential morbidity associated with surgery. Given that the registry data contain only limited information on underlying health status, it is not safe to compare the groups in terms of overall survival because many of the observed differences may be explained by unobserved confounding variables. Comparisons of BCSS should be less prone to this issue as the observed disease characteristics would be expected to have a more significant effect on this outcome. Higher rates of primary endocrine therapy in the UK than in many other developed countries could explain, at least in part, the inferior relative survival for breast cancer in this age group in the UK compared with that in a number of other developed nations. The present findings are similar to those of another UK cohort study 26 , which looked at outcomes in a cohort of 1065 patients aged over 70 years recruited between 1973 and 2009 at a single specialist centre in Nottingham, England. They demonstrated a difference in BCSS between patients treated with primary endocrine therapy and surgery at a population level. The magnitude of the difference was smaller, however, than was observed in the present registry cohort, and estimates of BCSS were also higher in both the surgery and primary endocrine therapy groups (95 and 84 per cent respectively) compared with the present cohort (89⋅9 and 69⋅4 per cent). The present data are from a larger cohort treated across multiple sites, rather than at a single hospital, and may therefore be more representative of practice across the whole country. In addition, the Nottingham cohort included very ER-rich early operable cancer; a subgroup analysis suggested that there was no difference in the effectiveness of the two approaches for women with strongly ER-positive tumours (H-score over 250). The H-score was not available for the registry cohort, so an equivalent analysis was not possible. The historical clinical trials comparing these treatment options suggested there was limited difference in effectiveness between the two approaches, but ER status was not measured in the majority of the trials. Even well conducted randomized trials are prone to external biases owing to issues of generalizability because of exclusion of patients with certain characteristics or deviations from everyday clinical practice. Routine registration data sets reflect outcomes as observed in real-life clinical practice, as compliance and adherence to endocrine therapy are likely to be worse in everyday practice than in a clinical study in which treatment is monitored more closely. Routinely collected data have the advantage of reflecting outcomes observed in clinical practice; registry data do, however, have some quality issues. In the present data set, there was a high proportion of missing values for a number of co-variables, especially for patients in the non-surgical group. For example, tumour size and clinical node status are not always recorded from imaging reports for these patients. Missing data were addressed using multiple imputation. This approach helps to mitigate against biases that can occur if patients with missing data are excluded and the missing data are connected to the characteristics of the individuals. This contrasts with the complete-case analysis approach taken by other models developed in the breast cancer field, for example PREDICT 27 . Missing data were less of an issue for the PREDICT model, which is based only on women treated surgically and includes younger patients who are more likely to have complete data. In the present study, staging data were missing for a number of patients; patients treated non-surgically are more likely to have incomplete staging information as non-pathological staging data have not always been recorded historically. Exclusion of all patients with missing stage at diagnosis would bias the results as the remaining sample would not be representative of the population as a whole. Inclusion of all patients with unknown stage would also be expected to bias the results; poorer survival outcomes in the primary endocrine therapy group may result from the inability to identify all patients who were treated non-surgically owing to the presence of advanced stage disease. For this reason, multiple imputation was performed using the whole data set. In each imputation, patients with known or imputed stage IV disease were excluded. The technique of multiple imputation used in this study has the advantage of propagating the uncertainty due to missing data into the estimates of co-variable effects. This is an attempt to avoid the biases that may occur when patients with missing data are excluded from analysis (and the missing data are connected to the characteristics of the data). This method is less prone to bias than other approaches to analysing registry data, such as complete-case analysis or treating 'missing' as a category in a factor variable. There is, however, no perfect method for accounting for missing data and it may not have accounted for all biases. Analysis of the multiply imputed data sets did not raise any concerns about the validity of the imputation approach. However, by definition it is not possible to compare against the true underlying values.
Observational studies are at risk of confounding between treatment allocation and outcomes, which leads to bias in estimates of treatment effects. The statistical techniques used in the present study mitigate against confounding that is due to factors observed in the data set. These techniques do not, however, account fully for the effects of confounders that are not observed in a data set, especially if there are confounders that are uncorrelated with observed co-variables. With respect to BCSS, it was hypothesized a priori that disease characteristics and age were primary confounders between the outcome and treatment choice. On the other hand, an unobserved characteristic such as frailty, which is not collected routinely by the registry, may be accounted for in part owing to its correlation with age and co-morbidity, and so is partially adjusted for in the various models. As a result, the key findings of the present study are unlikely to be explained primarily by confounding. By contrast, it is clear that these (health) factors could have a strong confounding effect with respect to death from non-breast cancer causes, and so overall survival was not considered.
The Kaplan-Meier curves for BCSS feature a sharper drop in the early part of the survival curve for the primary endocrine therapy group than for the surgery group, reflecting a number of early breast cancer deaths in this group. This pattern was not observed in comparable studies; for example, in the Nottingham cohort 26 the change in BCSS occurred gradually over time in both groups. One possible explanation for this is potential inaccuracy in recording of metastatic disease in the cancer registration data; for example, the record may not be updated if stage IV cancer is detected as a result of follow-up staging tests. Another possible explanation is the avoidance of surgery in the very frail and ill, who went on to receive primary endocrine therapy but died from other causes soon after diagnosis. Cause of death may be reported inaccurately. It is difficult to attribute death to a single cause, especially in the frail elderly, and in routine data breast cancer may be listed as the primary cause of death when in fact other causes were the primary contributor. Further research is needed to determine the extent to which routine data can be used to model survival outcomes accurately in this population, for example by collecting routine registration data alongside data collected specifically for a clinical study.
The present results suggest that, among older patients with ER-positive breast cancer, the risk of breast cancer death was greater in patients treated with primary endocrine therapy than in those who had surgery. This appears to contrast with RCT data from historical trials, although a trend in favour of surgery was revealed by meta-analysis 5, 28 and a significant advantage for surgery was shown on long-term follow-up of these studies 11 , so the outcome is not discordant. Surgery should be recommended for the majority of women, with primary endocrine therapy being reserved for those with limited life expectancy (owing to age, frailty or co-morbidity) or those who express a preference not to undergo surgery. Findings from this analysis have been used to develop a web-based clinical management algorithm to help clinical teams decide on best practice for an individual older woman. Evaluation of this tool is ongoing and the data from this study will be of value in predicting what may be expected for individuals in whom different treatment options are being considered. An ongoing prospective cohort study, part of the Bridging the Age Gap in Breast Cancer project 29 , will provide a more detailed data set to help assess the effects of surgery on survival and recurrence in older women. The research programme is also developing and evaluating a series of decision support instruments tailored to older women, to support them in deciding between surgery and primary endocrine therapy. This will be targeted at women for whom both options are likely to give good outcomes.
